Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 292

1.

Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications.

Carlsson A, Hansson LO, Waters N, Carlsson ML.

Life Sci. 1997;61(2):75-94. Review.

PMID:
9217267
2.

Decoding schizophrenia.

Javitt DC, Coyle JT.

Sci Am. 2004 Jan;290(1):48-55. No abstract available.

PMID:
14682038
3.

[A biochemical theory of schizophrenia].

Kornhuber HH, Kornhuber J, Kim JS, Kornhuber ME.

Nervenarzt. 1984 Nov;55(11):602-6. German.

PMID:
6151120
4.

Neurotransmitter interactions in schizophrenia--therapeutic implications.

Carlsson A, Waters N, Carlsson ML.

Biol Psychiatry. 1999 Nov 15;46(10):1388-95. Review.

PMID:
10578453
5.

Alterations of serotonin transmission in schizophrenia.

Abi-Dargham A.

Int Rev Neurobiol. 2007;78:133-64. Review.

PMID:
17349860
6.

[Physiopathology of schizophrenia. Some biologic aspects].

Tissot R.

Schweiz Arch Neurol Neurochir Psychiatr. 1984;135(1):29-40. French. No abstract available.

PMID:
6148787
7.

Integrating the neurobiology of schizophrenia. Preface.

Abi-Dargham A, Guillin O.

Int Rev Neurobiol. 2007;78:xiii-xvi. No abstract available.

PMID:
17349855
8.

Alterations of dopamine and serotonin transmission in schizophrenia.

Remington G.

Prog Brain Res. 2008;172:117-40. doi: 10.1016/S0079-6123(08)00906-0. Review.

PMID:
18772030
10.

The serotonergic system in the brain and its possible functional connections with other aminergic systems.

Samanin R, Garattini S.

Life Sci. 1975 Oct 15;17(8):1201-9. Review. No abstract available.

PMID:
574
11.

Neurotransmitter interactions in schizophrenia-therapeutic implications.

Carlsson A, Waters N, Carlsson ML.

Eur Arch Psychiatry Clin Neurosci. 1999;249 Suppl 4:37-43.

PMID:
10654107
12.

Regulation of neurotransmitter reuptake by nitric oxide.

Pögün S, Kuhar MJ.

Ann N Y Acad Sci. 1994 Nov 17;738:305-15. No abstract available.

PMID:
7832440
13.

Computational modeling of synaptic neurotransmission as a tool for assessing dopamine hypotheses of schizophrenia.

Qi Z, Miller GW, Voit EO.

Pharmacopsychiatry. 2010 May;43 Suppl 1:S50-60. doi: 10.1055/s-0030-1248317. Epub 2010 May 18.

PMID:
20486051
14.

[Biochemistry of schizophrenia and mechanism of action of neuroleptics].

Loo H, Cuche H, Sechter D.

Sem Hop. 1982 Dec 2;58(44):2565-72. Review. French.

PMID:
6130604
15.

Serotonin-dopamine interactions: implications for the design of novel therapeutic agents for psychiatric disorders.

Wood MD, Wren PB.

Prog Brain Res. 2008;172:213-30. doi: 10.1016/S0079-6123(08)00911-4. Review.

PMID:
18772035
16.

Mayo Seminars in Psychiatry: dopamine and schizophrenia--a review.

Fredrickson P, Richelson E.

J Clin Psychiatry. 1979 Sep;40(9):399-405. Review.

PMID:
39063
17.

Interaction between N-methyl-D-aspartic acid receptors and D1 dopamine receptors: an important mechanism for brain plasticity.

Scott L, Aperia A.

Neuroscience. 2009 Jan 12;158(1):62-6. doi: 10.1016/j.neuroscience.2008.10.020. Epub 2008 Oct 18. Review.

PMID:
19000746
18.

Antipsychotic drugs reverse the AMPA receptor-stimulated release of 5-HT in the medial prefrontal cortex.

Amargós-Bosch M, Adell A, Artigas F.

J Neurochem. 2007 Jul;102(2):550-61. Epub 2007 Mar 29.

19.

[Neurotransmitters in Huntington chorea (review)].

Barkhatova VP, Larskiĭ EG.

Zh Nevropatol Psikhiatr Im S S Korsakova. 1985;85(3):444-50. Review. Russian. No abstract available.

PMID:
2581405
20.

Schizophrenia: diverse approaches to a complex disease.

Sawa A, Snyder SH.

Science. 2002 Apr 26;296(5568):692-5. Review.

PMID:
11976442

Supplemental Content

Support Center